Kenvue, the consumer health and beauty giant behind Neutrogena, Aveeno and Listerine, has missed quarterly estimates as inflation and tariff pressure erode margins across its portfolio.
Kenvue is not alone. The wider mass beauty market is wrestling with the same cost structure, and its results offer an early read on how tariff exposure is landing on everyday brands.
Management reiterated its full-year guidance, a signal that the miss is a margin story rather than a demand collapse, but the market responded by marking the stock down.
The miss extends a difficult year for the company, which was spun off from Johnson & Johnson in 2023 to operate as a standalone beauty and self-care powerhouse.
